drugset / Trial / NCT05765773
An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older
Phase 2
Completed
200 enrolled
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
Non-randomizedParallel-groupSingle-blindPrevention
Summary
An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac) Produced by FSBSI "Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products" for Adults Aged 60 Years and Older
Timeline
- Start
- 2021-07-01
- Primary completion
- 2022-10-01
- Completion
- 2023-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoviVac | Vaccine | 0.5 ml | Intramuscular |